Astellas Pharma appoints new president of EMEA operations

4 March 2016

Japanese drug major Astellas Pharma (TYO: 4503) has appointed Yukio Matsui as president of EMEA operations, with responsibility for the company’s commercial operations in Europe, the Middle East and Africa, it has been announced.

Mr Matsui, who has served as senior vice president, head of marketing for Astellas’ global strategic products since April 2015, will begin his new role on April 1 this year.

Yoshihiko Hatanaka, president and chief executive of Astellas Pharma, said: “The appointment of Yukio Matsui as president of EMEA operations brings more than 30 years’ experience to the role – including various important positions in all four regions including Japan, Americas, EMEA and Asia/Oceania. This experience will be crucial in securing the future success of Astellas for all stakeholders and helping the organization to stay focused on our vision to be on the forefront of healthcare change to turn innovative science into value for patients.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK